Publications

Health policy (Amsterdam, Netherlands)

Coverage with evidence development programs: a scoping review on characteristics and patient access.

01-09-2026

The Lancet. Oncology

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

01-07-2026

The Lancet. Oncology

Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.

01-07-2026

International journal of cancer

Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study.

04-06-2026

Breast (Edinburgh, Scotland)

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

01-06-2026

Cancer treatment reviews

Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposal.

01-06-2026

Breast (Edinburgh, Scotland)

Towards patient-centered research in pregnancy-associated breast cancer: creating a science agenda through a priority-setting-partnership.

15-05-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

15-05-2026

Annals of oncology : official journal of the European Society for Medical Oncology

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

21-04-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

17-04-2026

Breast cancer research : BCR

Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.

25-02-2026

Breast cancer research : BCR

One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer.

30-01-2026

Journal of clinical pathology

Prognostic value of immunohistochemical markers of intratumoral hypoxia in pregnancy-associated breast cancer.

15-12-2025

Breast (Edinburgh, Scotland)

Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.

01-12-2025

ESMO open

Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

01-12-2025

Histopathology

Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.

01-12-2025

Journal of the National Cancer Institute

Breastfeeding after breast cancer in young BRCA carriers.

01-11-2025

The Lancet. Digital health

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

01-11-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

01-11-2025

Breast cancer research and treatment

Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort.

01-11-2025

Breast (Edinburgh, Scotland)

Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model.

01-10-2025

Lancet (London, England)

Balancing quality and quantity of life in older patients with breast cancer.

02-08-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01).

01-08-2025

ESMO open

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.

01-08-2025

Journal of the National Cancer Institute

Breast implant illness after reconstruction with silicone breast implants.

01-08-2025

European journal of cancer (Oxford, England : 1990)

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.

03-06-2025

The Lancet. Oncology

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.

01-06-2025

Breast (Edinburgh, Scotland)

Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC.

01-06-2025

The British journal of surgery

Three-year patient-reported outcomes of the BOOG 2013-08 RCT evaluating omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast conserving surgery: Impact of personality traits on health-related quality of life.

30-04-2025

Scientific reports

Case-only analysis in small studies of predictive biomarkers.

16-04-2025

MDM policy & practice

Bridging the Gap: A Mixed-Methods Study on Factors Influencing Breast Cancer Clinicians' Decisions to Use Clinical Prediction Models.

28-03-2025

European journal of cancer (Oxford, England : 1990)

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.

25-02-2025

NPJ breast cancer

Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.

19-02-2025

JAMA network open

Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

03-02-2025

ESMO open

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

01-02-2025

Nature

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

01-01-2025

Key Publication

European journal of cancer (Oxford, England : 1990)

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

01-12-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

20-10-2024

ESMO open

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

01-10-2024

Acta oncologica (Stockholm, Sweden)

High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers.

10-09-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

Cancer

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

15-08-2024

JAMA oncology

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

01-08-2024

Scientific reports

Cox proportional hazards regression in small studies of predictive biomarkers.

20-06-2024

Genome research

Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.

15-05-2024

The British journal of surgery

De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).

03-04-2024

JAMA

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

02-04-2024

JAMA network open

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.

01-04-2024

ESMO open

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

01-03-2024

Coverage with evidence development programs: a scoping review on characteristics and patient access.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.

Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study.

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposal.

Towards patient-centered research in pregnancy-associated breast cancer: creating a science agenda through a priority-setting-partnership.

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.

One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer.

Prognostic value of immunohistochemical markers of intratumoral hypoxia in pregnancy-associated breast cancer.

Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.

Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.

Breastfeeding after breast cancer in young BRCA carriers.

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort.

Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model.

Balancing quality and quantity of life in older patients with breast cancer.

Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01).

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.

Breast implant illness after reconstruction with silicone breast implants.

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.

Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC.

Three-year patient-reported outcomes of the BOOG 2013-08 RCT evaluating omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast conserving surgery: Impact of personality traits on health-related quality of life.

Case-only analysis in small studies of predictive biomarkers.

Bridging the Gap: A Mixed-Methods Study on Factors Influencing Breast Cancer Clinicians' Decisions to Use Clinical Prediction Models.

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.

Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.

Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers.

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

Cox proportional hazards regression in small studies of predictive biomarkers.

Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.

De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

This site uses cookies